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ABSTRACT 
 
Introduction: MicroRNAs (miRNAs) are small non-coding RNAs, with a length of 18 to 24 
nucleotides that play a regulative role in several cellular processes. Since their discovery, 
they have been identified in organs, tissues, cells and body fluids and their potential as 
molecular biomarkers for the diagnosis of various pathologic conditions, as well as for 
forensic body fluid identification has been explored. In the particular case of peripheral 
blood, this body fluid is normally seen as a whole despite the fact that there are several 
differences among its different fractions (plasma, serum and blood cells). One of these 
differences relies in the miRNA population, since that some miRNAs show different 
expression levels and patterns according to the fraction analyzed. Therefore, in order to 
standardize the results of studies involving miRNAs, and eventually the analysis of 
forensic evidences, it is extremely important to assess the miRNA expression pattern 
among the different fractions of peripheral blood and define a specific profile. 
Objectives: In this study we evaluated the miRNA expression pattern of miR-801, miR-
369-3p, miR-16-5p and miR-24-1-5p in the fractions of peripheral blood (plasma, serum, 
and white blood cells (WBCs)), in order to identify specific miRNAs of these fractions. 
Material & Methods: The peripheral blood samples were processed and the miRNAs 
were extracted from the serum, plasma and WBCs samples. Complementary DNA 
(cDNA) synthesis and quantitative real-time PCR were then performed, followed by a 
statistical analysis of the obtained results with the software IBM®SPSS®Statistics (Version 
22.0). 
Results & Discussion: We found that the analyzed miRNAs were differently expressed 
across the plasma, serum and WBCs samples tested. Our results indicated that miR-24-1-
5p was detected almost exclusively in WBCs and had a specificity of 81.82%, and a 
sensitivity of 90.91% for the identification of WBCs versus serum and plasma. 
Furthermore, miR-801, miR-369-3p and miR-16-5p exhibited the higher expression levels 
in serum, leading us to conclude that this is the optimal fraction for miRNA analysis. 
Additionally, as these three miRNAs could be found across all peripheral blood fractions 
tested, they could be biomarkers for whole blood identification. MiR-16-5p was found to be 
significantly more expressed in serum, in comparison to plasma and WBCs, however, in 
its use as a serum biomarker, one should take into account the influence of gender. We 
also found that, overall, the expression levels of the tested miRNAs didn’t exhibited any 
major differences between samples from individuals of different gender or age, what is an 
important factor in the development of biomarkers for forensic procedures, since a good 
biomarker should remain unaltered throughout the population, in order to allow the correct 
identification of the peripheral blood fraction regardless of individual characteristics. 
  Abstract 
 
microRNA biomarkers for peripheral blood fractions identification:   
possible forensic applications 16 
Furthermore, for miR-24-1-5p, the odds ratio (OR), specificity, sensitivity, positive 
predictive value or precision (PPV), negative predictive value (NPV) and accuracy (ACC) 
values remained elevated regardless of gender and age sub-divisions. 
Conclusion: Our results indicate that miR-801, miR-369-3p and miR-16-5p have the 
potential to be biomarkers for whole peripheral blood identification. However, before its 
implementation in forensic analysis, further studies with other body fluids are needed, in 
order to confirm whether or not they can be found in other body fluids. Moreover, miR-16-
5p could also be a biomarker for serum identification and miR-24-1-5p for WBCs 
identification. 
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RESUMO 
 
Introdução: Os microRNAs (miRNAs) são pequenas moléculas de RNA não codificante, 
com um comprimento de 18 a 24 nucleótidos, que desempenham um papel regulador em 
diversos processos celulares. Desde a sua descoberta, os miRNAs têm sido detetados 
em órgãos, tecidos, células e fluidos corporais, sendo que o seu potencial como 
biomarcadores moleculares para o diagnóstico de várias condições patológicas, assim 
como para a identificação forense de fluidos corporais tem sido explorado. No caso 
particular do sangue periférico, este fluido corporal é normalmente visto como um todo, 
apesar do facto de apresentar várias diferenças entre as suas frações (plasma, soro e 
células sanguíneas). Uma destas diferenças consiste no padrão de expressão de 
miRNAs, uma vez que alguns miRNAs apresentam diferentes níveis e padrões de 
expressão de acordo com a fração analisada. Desta forma, torna-se relevante o 
estabelecimento do perfil de miRNAs específico associado às diferentes frações de 
sangue periférico, o que poderá ser muito útil em Medicina Legal, nomeadamente na 
análise de provas forenses.   
Objetivos: Neste estudo avaliou-se o padrão de expressão dos miRNAs miR-801, miR-
369-3p, miR-16-5p e miR-24-1-5p, nas diferentes frações de sangue periférico (plasma, 
soro e leucócitos), de modo a identificar miRNAs específicos destas frações. 
Material & Métodos: As amostras de sangue periférico foram processadas e os miRNAs 
foram extraídos a partir das amostras de soro, plasma e leucócitos. Após a síntese de 
DNA complementar, os miRNAs foram analisados por PCR quantitativo em tempo real e 
os resultados obtidos foram analisados estatisticamente com recurso ao software 
estatístico IBM®SPSS®Statistics (Versão 22.0).  
Resultados & Discussão: Verificou-se que os miRNAs analisados se encontravam 
diferencialmente expressos nas amostras testadas de plasma, soro e leucócitos. Os 
resultados indicaram que o miR-24-1-5p foi detetado quase exclusivamente em 
leucócitos, apresentando uma especificidade de 81,82% e uma sensibilidade de 90.91% 
para a identificação de leucócitos versus soro e plasma. Adicionalmente, o miR-801, o 
miR-369-3p e o miR-16-5p exibiram níveis de expressão mais elevados no soro, o que 
leva a concluir que esta é a fração ideal para a análise de miRNAs. Atendendo que estes 
três miRNAs podem ser encontrados em todas as frações de sangue periférico testadas, 
podemos considerar que estes poderão ser potenciais biomarcadores para a identificação 
de sangue total. O miR-16-5p apresentou uma expressão significativamente mais elevada 
no soro, em comparação com o plasma e os leucócitos, no entanto, a sua utilização como 
um biomarcador de soro deve ser feita com precaução atendendo à influência do género 
encontrada no presente estudo. Observamos também que, de um modo geral, os níveis 
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de expressão dos miRNAs testados não exibiram diferenças significativas entre amostras 
de indivíduos de diferente género ou idade, o que é um fator importante no 
desenvolvimento de biomarcadores para procedimentos forenses, uma vez que um bom 
biomarcador deve manter-se inalterado em toda a população, de modo a permitir uma 
correta identificação da fração de sangue periférico. Quanto ao miR-24-1-5p, verificamos 
que os valores de razão de possibilidades, especificidade, sensibilidade, valor preditivo 
positivo ou precisão, valor preditivo negativo e acurácia permaneceram elevados 
independentemente das sub-divisões de género e idade. 
Conclusão: O miR-801, o miR-369-3p e o miR-16-5p apresentam um elevado potencial 
de serem biomarcadores moleculares úteis na identificação de sangue periférico. Porém, 
antes da sua implementação nas análises e procedimentos forenses, são necessários 
estudos adicionais que comparem outros fluidos corporais, de modo a confirmar se estes 
miRNAs podem ou não ser encontrados noutros fluidos. O presente estudo revelou ainda 
que o miR-16-5p poderá ser um biomarcador para a identificação de soro e o miR-24-1-
5p para identificação de leucócitos. 
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1. INTRODUCTION 
 
The different fractions of peripheral blood (serum, plasma and blood cells), despite 
being normally seen as a whole, show several differences among them. This is the case 
of the protein fibrinogen, which can be found in plasma, but is absent in serum [1]. Other 
variation between the fractions is the microRNA (miRNA) expression levels within the 
different peripheral blood fractions. In the literature there are some studies that point to 
the differentiated expression of certain miRNAs in blood fractions, however given the lack 
of information in this area, a better characterization of the miRNA content is needed [2, 3]. 
Therefore, it is important to address this subject in order to, not only, establish and 
characterize the existing differences, but also to standardize the methodologies used. 
Thus, once the miRNA expression pattern in the peripheral blood fractions is established it 
will facilitate and allow the implementation of miRNA analysis in forensic procedures. 
 In fact, in comparison to other nucleic acids, such as the deoxyribonucleic acid 
(DNA) and the messenger ribonucleic acid (mRNA), miRNAs are smaller, what makes 
them more stable and less prone to degradation [4, 5]. Moreover, these molecules exhibit 
different expression profiles according to the tissues or body fluid tested [5]. Due to these 
characteristics, they have a great potential of being reliable and efficient biomarkers for 
body fluid characterization, as well as for the diagnosis of pathologic conditions. 
 
 
1.1. microRNAs 
 
MiRNAs are short non-coding RNA, with a length of 18 to 24 nucleotides that play 
a regulative role in several cellular processes. Currently, there are, approximately 1881 
known sequences of human miRNAs (miRBase release 21.0) [6, 7]. 
MiRNAs are transcribed from the genomes of nucleated cells by RNA polymerase 
II or III and these primary miRNA transcripts (pri-miRNAs) are then modified by the 
addition of a 5’ cap and a 3’ poly-A tail [4]. Subsequently, the pri-miRNAs are processed 
first in the nucleus by the ribonuclease  (RNase) III enzyme Drosha, being later exported 
by Exportin 5 to the cytosol, where they are processed by the RNase III enzyme Dicer [4, 
8]. This processing of pri-miRNAs originates initially a miRNA precursor (pre-miRNA) with 
approximately 70 nucleotides of length, and finally a smaller and mature double-stranded 
miRNA of 18–24 nucleotides [4, 8]. One strand of this mature miRNA is incorporated in 
the RNA-induced silencing complex (RISC), where it can regulate the expression of target 
mRNAs [4]. This miRNA can induce post-transcriptional gene silencing, through the 
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guidance of the RISC complex to the target mRNAs, or mRNA cleavage and degradation 
(Figure 1) [8, 9]. The RISC complex is also responsible for the process RNA interference, 
in which a double-stranded RNA silences the expression of homologous genes by mRNA 
cleavage [8, 10-12]. The other strand could be degraded, or prepared for being exported 
from the cell [4]. Thus, miRNAs could be found not only on the intracellular compartments, 
but also in the extracellular microenvironment, namely in serum, plasma and urine [13]. 
However, there is little information concerning the subject of the origin of circulating 
miRNAs (both in healthy and sick individuals) and what factors may influence the levels of 
circulating miRNAs [14]. 
 
 
 
 
Figure 1 – Biogenesis and post-transcriptional suppression of microRNAs. MiRNAs are transcribed from the 
genomes of nucleated cells into pri-miRNA transcripts, which are processed by Drosha in the nucleus, 
originating ~70-nucleotide pre-miRNAs. These pre-miRNAs are transported to the cytoplasm by Exportin 5 
and are processed by Dicer into a mature double-stranded miRNA of 18-24 nucleotides. One strand of this 
miRNA is incorporated into the RNA-induced silencing complex (RISC), which later can induce translational 
repression or mRNA cleavage. 
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Nevertheless, when compared to DNA and mRNA, the small size of miRNAs 
makes them more stable and, therefore, less prone to degradation, making them good 
options for the development of biomarkers. Another factor that plays a key role in their 
stability is the argonaute (AGO) proteins, which are a catalytic component of the RISC 
complex [10-12, 15]. The interaction of AGO proteins with mature miRNAs makes them 
much more stable to the degradation process [6, 11, 16]. In fact, Chen and colleagues 
demonstrated that serum miRNAs were able to remain stable even after being exposed to 
severe environmental conditions, like high temperatures, extreme pH and prolonged 
storage [17]. 
Another characteristic of miRNAs is the differential expression of these molecules 
among tissues and fluids [4, 5]. For example, the miR-124 is considered a brain-specific 
miRNA and miR-122 is highly expressed in liver [3, 4, 18, 19]. Alterations on the normal 
miRNA expression pattern have also been associated with a diversity of pathologic 
conditions, such as cancer or cardiac diseases [19-28]. 
In fact, an ideal biomarker should have a series of characteristics, such as being 
accessible through non-invasive methods, being inexpensive to quantify, it must be 
specific to the disease or physiologic condition of interest and translatable from model 
systems to humans and, in the case of biomarkers for pathologic conditions, it should be a 
reliable early indicator of disease before the appearance of clinical symptoms [5]. Since 
miRNAs have these characteristics, they are very promising when it comes to the 
development of new non-invasive biomarkers [5]. However, some authors have suggested 
that the concentration for some miRNAs may be affected by gender and age, and due to 
the fact that an ideal biomarker should maintain unaltered, this information emphasizes 
the need of further studies, in order to uncover the miRNAs that are stable and that exhibit 
higher potential of being good biomarkers [11, 29]. 
 
 
1.2. Peripheral blood fractions 
 
The different fractions of peripheral blood, which include plasma, serum and blood 
cells – leucocytes or white blood cells (WBCs), erythrocytes or red blood cells (RBCs) and 
platelets – differ from each other based on several factors [1]. Serum and plasma doesn’t 
contain cells, as opposite to blood cells. Both serum and plasma contain hormones, 
glucose, electrolytes, antibodies, antigens and other particles. Plasma corresponds to the 
cell-free supernatant resulting from centrifuged blood collected in the presence of an 
anticoagulant [30]. On the other hand, serum is the cell-free supernatant resulting from 
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centrifuged blood collected in the absence of an anticoagulant, therefore, serum does not 
contain the most of the clotting factors, such as the fibrinogen, and cannot clot [30]. Based 
on these definitions, it is possible to conclude that the main difference between these two 
fractions relies on the presence/absence of clotting factors and associated proteins. 
Furthermore, during the process of coagulation, blood cells can secrete a variety of 
components that contribute to the different composition of plasma comparing to serum [1]. 
Particularly, platelets contribute with diversity of components to blood serum, such as the 
vascular endothelial growth factor [1].  
Serum and plasma also differ in their protein content. The protein concentration in 
plasma is higher than in the serum [1]. The main types of proteins existent in the plasma 
are albumin, globulin, and fibrinogen, while the main protein components of serum 
consists of albumin, immunoglobulins, transferrin, haptoglobin, and lipoproteins  [31, 32]. 
Additionally, plasma contains the Von Willebrand factor, a protein that mediates the 
initiation and progression of thrombus formation at sites of vascular injury, thus 
contributing to platelet function [33]. 
A study performed by Twomey and co-workers assessed the differences among 
serum and plasma parathyroid hormone (PTH) measurements in patients with chronic 
renal failure and found significant differences in the intact-PTH concentration between 
serum and EDTA (Ethylenediaminetetraacetic Acid) plasma in routine clinical practice 
[34]. This study showed that the differences between these two fractions of peripheral 
blood should be considered both in clinical and forensic studies [34].  
Recently, it has been accepted that the fractions of peripheral blood also differ in 
their miRNA content. 
 
 
1.3. Extracellular/circulating microRNAs 
 
The extracellular miRNA group is diverse, considering some miRNAs can be 
packaged into apoptotic bodies, microvesicles (MVs), or high density lipoprotein (HDL) 
particles, while others are exclusively complexed with AGO proteins [3]. The vesicles 
group comprising both shedding vesicles and exosomes is frequently designated as MVs 
[25]. Apoptotic bodies are particles with a size that can range between 1 to 4m and that 
remain after programmed cell death initiation [3]. Shedding vesicles are heterogeneous 
vesicles (100-1000 nm) that are released by outward budding and fusion of the plasma 
membrane, whereas exosomes are smaller vesicles (30–100 nm) that are released 
following the fusion of endosomal-derived multivesicular bodies with the plasma 
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membrane [4, 25]. MiRNAs have been identified in exosomes and microvesicles 
recovered from different body fluids, such as plasma, serum, saliva and urine [4, 35]. 
According to Arroyo and co-workers, the majority of circulating miRNAs are protein 
bound, rather than associated with vesicles [36]. Moreover, Turchinovich and colleagues 
corroborates this information, showing that extracellular miRNAs are mainly 
exosomes/microvesicles free and are associated with AGO proteins [37]. When plasma 
blood fraction is analyzed the situation is similar, as 90-95% of the totality of miRNAs in 
cell-debris-free blood plasma is circulating in an AGO-protein-bound form, while the 
microvesicle-associated miRNAs are a minority [3, 36, 37]. On the other hand, Gallo and 
co-workers found that the majority of miRNAs detectable in the serum of healthy 
individuals and systemic lupus erythematosus patients are primarily in exosomes content 
[35]. This divergence in the results supports the need to clarify these evidences and the 
need of additional studies. Moreover, although several miRNAs were detected in purified 
fractions of high density lipoproteins (HDL) from human plasma, their proportion in blood 
plasma is still unknown [3, 38]. Regarding the miRNAs packaged into apoptotic bodies, 
there is a lack of information concerning their contribution to the circulating miRNA 
population. Furthermore, in this situation, the fact that the size of apoptotic bodies is 
similar to that of cell debris and blood platelets and that the protocols frequently used in 
extracellular miRNA isolation involve the elimination of cell debris and apoptotic bodies, 
this may cause an overlook of the cell-free miRNA in these fractions [3]. 
 
 
1.4. Origin of circulating plasma and serum microRNAs  
 
For most miRNAs present in plasma and serum their specific cellular origin is 
unknown, however the pattern expression of a vast number of miRNAs is established, 
making it possible to determine its probable source (Figure 2) [3, 25, 39]. 
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Figure 2 – Blood vessel containing plasma, blood cells (RBCs, platelets and WBCs) and endothelial cells, as 
well as the main miRNAs present in (a) plasma and endothelial cells and (b) plasma and blood cells. These 
plasma/serum miRNAs may be released by endothelial cells or/and blood cells into plasma, and thus derived 
from these cells.  
 
 
Here, we further explore the possibility of an endothelial, blood cell and organ 
origin of some miRNAs present in plasma and/or serum and suggest the hypothesis that 
some miRNAs could originate from both endothelial and blood cells (Table 1). Since the 
miRNAs released from blood cells into plasma and serum are determined it would be 
interesting to study the alterations in the miRNA expression pattern amongst individuals 
with blood-related diseases in order to assess possible associations. We may consider 
that this can also have forensic implications, as it can be useful to the identification of the 
donor of a body fluid. For example, in a crime scene, in which was found a possible blood 
stain, but that sample is not viable for DNA extraction and analysis, since miRNAs are 
much more stable, this same sample might allow a miRNA analysis [4, 5]. Thus, in this 
particular situation, the elaboration of a miRNA expression profile might indicate specific 
pathologies of the sample donor, which could be essential information to narrow down the 
suspects list. 
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Table 1 – Overall of the different origins of several circulating human miRNAs. 
 
 
1.4.1. Circulating microRNAs derived from endothelial cells 
 
The endothelium is constituted by a monolayer of cells (endothelial cells) and it is 
present in the internal cellular lining of the blood vessels (arteries, veins and capillaries) 
and the lymphatic system, thus interacting directly with the blood and lymph  [67]. For this 
reason, it is logical to suggest that plasma and serum miRNAs that are also highly 
expressed in endothelial cells may derive from these cells. 
For example, according to Zhou and co-workers, miRNAs encoded by the miR-
23∼27∼24 gene clusters, such as miR-23a, miR-23b and miR-27a, are known to be more 
highly expressed in endothelial cells and in highly vascularized tissues [52]. Although 
these miRNAs are present in plasma, serum and blood cells, when McCall and co-
workers evaluated their expression in endothelial, epithelial and hematologic cells, they 
found that they are more highly expressed in endothelial cells rather than in hematologic 
cells [29, 46]. Particularly, the expression of miR-23a and miR-23b was detected in 
endothelial cells by seven different profiling studies, being the miR-23a highly expressed 
in endothelial cells [41-44, 48-50, 57]. Similarly, miR-27a, which belongs to the miR-27 
gene family, was detected in endothelial cells by five profiling studies [41, 42, 44, 49, 51]. 
Origin miRNAs     References 
Endothelial 
 
miR-23a 
 
 
miR-23b 
 
miR-27a 
 
miR-125b 
 
miR-135a-3p 
[5, 7, 23, 27, 
29, 40-52] 
miR-222 miR-296 miR-409-3p miR-499 
 
 
 
Blood cell 
 
 
miR-150 
 
miR-223 
 
miR-451 
 
miR-486-5p 
 
miR-574-3p 
[14, 29, 45, 
46, 53, 54] 
 
Endothelial and 
blood cell 
 
 
let-7a 
 
miR-16-5p 
 
miR-22 
 
miR-126 
 
[5, 27, 29, 41-
46, 48, 50, 53, 
55-59] 
 
Organ  
 
 
Kidneys 
 
 
miR-192 
 
 
miR-194 
 
 
miR-204 
 
 
miR-215 
 
 [5, 29, 60, 61] 
 
Liver 
 
 
miR-122 
 
 
miR-148 
 
   
[3, 5, 18, 19, 
29, 62-64] 
 
Brain 
 
 
miR-124 
 
 
miR-128 
 
 
miR-129-5p 
 
 
miR-191 
 
 
miR-342-3p 
 
[3, 5, 19, 29, 
62] 
 
Lungs 
 
 
miR-21 
 
 
miR-30b 
 
 
miR-30c-1 
 
 
miR-146b-5p 
 
 [5, 29, 39] 
 
Cancer 
cells 
 
 
miR-7 
 
miR-210 miR-221 miR-195 miR-375 [3, 20, 24, 
26, 65, 66] 
 miR-1233     
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MiR-125b and miR-409-3p can also be found in plasma and serum and although 
Wang and colleagues reported that these miRNAs are also present in blood cells, McCall 
and co-workers observed that miR-409-3p was specific of endothelial cells, presenting 
high expression levels in these cells and that miR-125b was expressed in endothelial and 
epithelial cells, and not in hematologic cells [5, 29, 46]. Moreover, the miR-125b 
expression in endothelial cells was confirmed by six profiling studies [41, 42, 48, 49, 51, 
57]. 
MiR-222 can also be detected in plasma, serum and blood cells of healthy 
individuals, however, it is more expressed in endothelial cells, rather than in hematologic 
cells [29, 46]. This miRNA is involved in the endothelial cell function and seven profiling 
studies reported its expression in endothelial cells [27, 41, 42, 44, 45, 49-51, 57]. 
Furthermore, the fact that this miRNA is highly expressed in endothelial cells makes it 
more likely that the plasma/serum miR-222 originates from the endothelium, rather than 
from blood cells [43, 49]. Interestingly, a recent (and not yet published) study of our group 
presented evidence that when it comes to the miRNA analysis of blood cells and urine, 
miR-222 presents a constant expression pattern between these two body fluids [68]. 
Considering the expression pattern of miR-222 in endothelial cells, it would be interesting 
to study the same expression pattern in pathologies involving alterations in endothelial 
cells, such as cancer.  
MiR-135a*, a miRNA that according to miRBase is now referred to as miR-135a-
3p, is present in plasma and absent in blood cells [5, 7, 29]. Additionally, considering that 
this miRNA is expressed in endothelial cells and is not expressed in hematologic cells, the 
miR-135a-3p present in plasma  can have an endothelial origin [46]. 
Another plasma miRNA that could be derived from endothelial cells is miR-296, 
since it is present in the plasma of healthy individuals and it has been detected in two 
endothelial miRNA profiling studies [41, 42, 47]. Similarly to miR-222, since miR-296 is 
present in endothelial cells of healthy individuals, this miRNA is also a good candidate to 
display expression alterations in certain types of pathologies and, therefore has potential 
to be studied in other types of populations. 
Lastly, the miR-499, although its low expression levels in healthy individuals, this 
miRNA was detected in the blood plasma of healthy individuals and is highly expressed in 
endothelial cells, being produced almost exclusively in the heart [23, 40, 49]. The fact that 
this miRNA has low expression levels in the plasma of healthy individuals and is produced 
in the heart suggests that it might be highly expressed in individuals who exhibit cardiac 
diseases. 
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1.4.2. Circulating microRNAs derived from blood cells 
 
The presence of miRNAs in WBCs is easily understood, as these cells have 
nucleus. However, when considering the platelets and RBCs the situation is different, 
since these cells do not have nuclei, and, therefore it is frequently thought that they do not 
contain nucleic acids. Chen and co-workers addressed this subject through the analysis of 
the transcriptome of a purified population of human mature erythrocytes from individuals 
with normal hemoglobin and homozygous sickle cell disease, finding that the miRNA 
expression in human mature erythrocytes is dramatically altered in homozygous sickle cell 
disease erythrocytes [69]. Additionally, their results indicated that the presence of miRNAs 
in RBCs may be attributed to the longer half-life and slower decay kinetics of specific 
miRNAs [69]. The explanation for this relies on the fact that miRNAs still exist in the 
functional form in reticulocytes, and that their immediate precursor, orthochromatic 
normoblasts, still contains nuclei [69]. Taking into consideration that the reticulocyte stage 
lasts for 40 hours, the reticulocyte miRNA synthesized in the orthochromatic normoblast 
persists in reticulocytes [69]. After the terminal differentiation, these miRNAs could persist 
in the mature erythrocytes [69]. Regarding the origin of platelet miRNAs, Landry et al. 
referred that pri-miRNAs are likely encoded by the genome of megakaryocytic precursor 
cells and converted into pre-miRNAs before platelet formation [70]. However, the fact that 
the mature miRNA species are much more abundant than their pre-miRNA counterparts 
supports the hypothesis that a large percentage of the mature miRNA content of platelets 
could be inherited directly from megakaryocytes [70]. Considering this information, in 
theory, healthy individuals should exhibit the same miRNA pattern in platelets, as opposed 
to individuals’ carriers of diseases that affect precursor cells, whose platelets miRNA 
patterns should present alterations. This is another interesting line of work, since that, as 
referred early, the information about the pathologies of the blood sample donor might play 
an important role in the identification of suspects and/or victims in a forensic investigation. 
MiR-223 is present in plasma, serum and blood cells – WBCs, RBCs and platelets 
– and although activated platelets can release miR-223 through microparticles (MPs) that 
can be internalized by endothelial cells, Mayr and co-workers reported that this particular 
miRNA is abundant in platelets and shows low expression levels in endothelial cells [29, 
45, 54]. Interestingly, Pritchard et al. found that the plasma levels of this myeloid-enriched 
miRNA, closely tracked with changes in myeloid blood counts, such as platelets and 
neutrophils [14]. Based on this data, it is possible to conclude that the probable origin of 
the miR-223 is the blood cells, rather than the endothelium. 
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In the same way, miR-150 is present in plasma, serum, WBCs, RBCs and platelets 
and Pritchard et al. detected that the plasma levels of this lymphoid-enriched miRNA 
reflected lymphoid counts [14, 29]. 
Plasma/serum miR-451 and miR-486-5p might also originate in blood cells, since 
these miRNAs are both common to the cellular and the circulation miRNAs populations, 
being present in plasma, serum, WBCs, RBCs and platelets, being specially enriched in 
RBCs [14, 29, 53]. 
Interestingly, miR-223, miR-150, miR-451 and miR-486-5p are highly expressed in 
hematologic cells and are absent in endothelial cells and in epithelial cells [46]. 
The expression of miR-574-3p is detected in plasma, serum, WBCs, RBCs and 
platelets, being  expressed in hematologic cells and not in endothelial cells [29, 46]. 
Additionally, the plasma levels of this miRNA presented significant positive correlations 
with myeloid blood cell counts, such as neutrophils and platelets [14]. 
 
 
1.4.3. Circulating microRNAs derived from endothelial and blood cells 
 
Other circulating plasma and serum miRNAs, like miR-126, miR-22, miR-16 
(currently referred to as miR-16-5p) or let-7a, which exhibit high expression levels in both 
blood cells as well as endothelial cells, could be equally secreted by these two types of 
cells into plasma/serum [5, 27, 29, 41-46, 48-50, 53, 55-59]. 
MiR-126, which is present in whole blood, as well as in plasma and serum, was 
reported to be an endothelial cell-restricted miRNA, highly expressed in the endothelium, 
blood vessels, heart, and lung and is involved in the endothelial cell function, suggesting 
an endothelial origin [27, 29, 55, 56, 58]. However, this miRNA was also identified in blood 
cells – WBCs, RBCs and platelets, and, although being present at lower levels in platelets 
that in endothelial cells, the shedding of platelet microparticles in plasma or serum also 
represents a major contributor to circulating miR-126 levels [29, 45]. 
Likewise, miR-22 is present in plasma, serum, WBCs, RBCs and platelets, being 
also highly expressed in endothelial cells [5, 29, 43]. 
MiR-16-5p is present in plasma, serum, WBCs, RBCs and platelets and it is 
particularly abundant in erythrocytes and endothelial cells [29, 59]. Moreover, this miRNA 
was detected in endothelial cells by six profiling studies [41, 42, 44, 48, 49, 57]. 
Let-7a, a miRNA present in plasma, serum and blood cells, common to the cellular 
and the circulation miRNAs populations and detected in endothelial cells by six profiling 
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studies is another candidate of a miRNAs derived both from endothelial and blood cells 
[29, 41, 42, 44, 49, 50, 53, 57]. 
Furthermore, McCall et al. observed that miR-22, miR-16-5p and let-7a are 
common to endothelial, epithelial and hematologic cells, and that miR-126 is expressed by 
endothelial and hematologic cells, supporting the hypothesis of a shared origin of these 
miRNAs in plasma and serum [46]. 
All these circulating plasma/serum miRNA that might have originated from both 
endothelial and blood cells could be differentiated by those which are derived by only one 
of these sources based on theirs expression levels in plasma and serum. It would be 
expected that the miRNAs that are secreted into the plasma/serum by both endothelial 
and blood cells would have higher levels in these fluids, when compared to the ones that 
are secreted either from endothelial or blood cells. As a future perspective it would be 
interesting to further explore this possibility in order to enlighten the miRNA origin in blood 
plasma and serum. 
 
 
1.4.4. Circulating microRNAs with an organ origin 
 
Due to the fact that some tissue-specific miRNAs have been identified in plasma, 
and when we consider the close contact between organs and the bloodstream, we can 
conclude that a miRNA transfer between these organs and the blood plasma/serum can 
occur [3]. Particularly, in highly vascularized organs, such as kidneys, liver, brain and 
lungs, this miRNA transfer between organs and blood plasma might represent a more 
significant contribution for the circulating miRNAs. For this reason, some plasma miRNAs 
may be organ-derived (Figure 3). 
Sun et al. detected five miRNAs, including miR-192, miR-194, miR-204, miR-215 
and miR-216, which were preferentially expressed in human kidney when compared with 
other organs/tissues, such as heart, spleen, lung, muscle and prostate [61]. Later, 
Chandrasekaran and co-workers, profiled the miRNA expression in human organs, 
including the kidneys, and concluded that these five miRNAs are among the few miRNAs 
that were found to be renal-specific [60]. Of these five miRNAs, miR-192, miR-194, miR-
204 and miR-215 can be found in plasma and since they are preferentially highly 
expressed in the kidney, this organ might secrete them into the bloodstream, and 
consequently, they may have a kidney origin [5, 29, 60, 61]. 
Regarding normal human liver tissues, very few circulating plasma miRNAs are 
reported to be highly expressed in this organ. Perhaps the most well studied miRNA in 
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liver is miR-122, a highly expressed miRNA that represents 70% of the total miRNA pool 
of this organ [18]. This miRNA is also a liver-specific miRNA that can be detected in 
plasma, and therefore its origin in plasma might derive from the liver [3, 19, 29, 64]. 
Likewise, miR-148, a miRNA that can be also found in plasma presents high expression in 
the adult liver and the results of Barad et al. validated the liver-specific expression of miR-
148 [5, 62, 63]. 
In the case of the brain, miR-124 is considered a brain-specific miRNA that have 
also been detected consistently in blood plasma, and therefore could be brain-derived [3, 
19]. Similarly, miR-128 is present in plasma and serum and was also reported to be a 
brain-specific miRNA [5, 29, 62]. Other similar miRNAs are miR-129-5p, miR-191 and 
miR-342-3p, since that they can be found in blood plasma and exhibit high expression 
levels in brain in comparison with other tissues, according to miRNAMap [5, 29, 39]. 
In the lungs, according to miRNAMap, miR-21, miR-30b, miR-30c-1 and miR-
146b-5p, are highly expressed in this organ, compared with others organs and tissues 
[39]. These miRNAs are also present in plasma and serum and based on theirs 
expression profiles, in the circulation they probably originate in the lungs, as a result of the 
lung irrigation process [5, 29]. 
Recent studies have also demonstrated a correlation between some miRNAs and 
specific pathologic conditions, such as cancer [3, 20, 24, 26, 65, 66]. Furthermore, since 
tumor cells can secrete miRNAs into the bloodstream, some studies, such as the one 
performed by Turchinovich et al., have considered the tumor as an organ that contributes 
to the blood miRNA population [3]. For example, the expression of serum miR-375 was 
reported to be greater in prostate cancer patients than in healthy individuals, and greater 
in metastasized cancer than in primary prostate cancer, what leads to believe that in 
individuals with this pathologic condition, this particularly serum miRNA could be 
originated in the cancer cells [26]. Moreover, this is corroborated by the study performed 
by Brase et al., in which was found that miR-375 was highly expressed in serum of 
prostate cancer patients and the release of this miRNA into the bloodstream is further 
associated with advanced disease [20]. Another miRNA in a similar situation is miR-195. 
This miRNA is present in the plasma of healthy individuals and its levels were 
considerably elevated in samples of whole blood of patients diagnosed with breast cancer 
from stage I to IV, when compared to age-matched disease-free individuals [5, 24, 26]. In 
this study the expression of miR-195 in age- and stage-matched tumor tissues was also 
compared with whole blood samples and the result was that in tumor tissues and 
circulation, the levels of miR-195 were increased at progressive stages of breast cancer. 
In other words, this miRNA was more expressed in stage IV than in stage I or II [24]. This 
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positive correlation between tissue and circulating miR-195 suggests that this miRNA 
could be released into the blood by the tumor cells. MiR-221 is another example of a 
miRNA associated with cancer, more specifically, with the renal cell carcinoma (RCC) 
[66]. Teixeira et al. reported that patients with higher plasma levels of this miRNA 
presented a significantly lower survival rate, when compared to those with lower 
expression levels, thus, revealing miR-221 as an independent prognosis factor in RCC 
[66]. Furthermore, the plasma expression levels of miR-221 were higher in patients with 
advanced disease (metastasis at diagnosis) comparatively with patients with localized 
disease [66]. MiR-210 and miR-1233 are other miRNAs that are implicated in the RCC, 
since a recent study (and not yet published) revealed that these miRNAs presented higher 
expression levels in plasma samples of RCC patients, when compared to healthy 
individuals, being good candidates for biomarkers of prognosis and aggressiveness in 
RCC. The expression levels of peripheral whole-blood miR-221 and miR-7 were also 
reported to be implicated as potential predictive biomarkers of castration-resistant prostate 
cancer development [65]. 
 
Figure 3 – Overview of several circulating plasma/serum miRNAs organ-derived. Adapted from 
http://upload.wikimedia.org/wikipedia/commons/6/6b/Man_shadow_with_organs.png [71] 
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1.5. Forensic applications of microRNAs as biomarkers for peripheral blood 
fractions characterization 
 
MiRNAs biomarkers for peripheral blood fractions exhibit a wide variety of forensic 
applications. 
One of the main aspects in the identification of miRNAs specific to peripheral blood 
fractions is to characterize the differences/variations existent within blood. This factor 
should be considered, not only in forensic sciences, but also in all the sciences that use 
miRNAs, since that in several studies is selected one fraction in particular without taking 
into account this variation. For this reason, the miRNA differences in the peripheral blood 
fractions should be analyzed in order to correctly select one of them according to the 
purpose of the study. 
Another forensic application of miRNAs biomarkers for peripheral blood fractions is 
related to body fluid identification. In fact, during a forensic investigation the correct 
identification of the possible body fluids found is crucial in order to identify possible 
sources for DNA collection to be later used in the identification of the donor of the biologic 
material [13]. Within this purpose, over the years, several methods were developed 
towards the body fluid identification, such as serologic tests [11]. However, these 
methodologies exhibit low sensitivity and specificity levels [11]. Thus, due to the small size 
of miRNAs, theirs increased stability and the fact that they show different expression 
profiles according to the tissue or fluid tested, recently they have been studied, not only as 
a resource in the diagnostic of different pathologic conditions, but also as an alternative to 
the conventional methods for the forensic body fluid identification. Although miRNA 
profiling is not currently a standard technique in forensic investigation, with the 
improvement of miRNA knowledge and respective methods, it could eventually be 
implemented in forensic procedures.  Furthermore, given the high stability of miRNAs and 
the fact that these potential biomarkers can be detected even in degraded samples – 
which are normally not legally allowed – in the future, miRNAs could lead to a change in 
legislation, allowing the acceptance of these types of samples as forensic evidence. This 
would represent a major progress and improvement in forensic investigations and 
evidence analysis. In the literature there are several studies about the use of miRNA 
biomarkers in the identification of body fluids [5, 13, 56, 72]. Courts and Madea analyzed 
the presence of miRNAs in blood and saliva samples of five healthy donors and presented 
two miRNA assays consisting of three differentially expressed miRNAs for the 
identification of blood (miR-126, miR-150, miR-451) and saliva (miR-200c, miR-203, miR-
205) [56]. On the other hand, Hanson and co-workers evaluated the miRNA expression 
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profile in dried, forensically relevant biological fluids (such as blood, semen, saliva, vaginal 
secretions, and menstrual blood) of healthy individuals to identify possible body fluid-
specific miRNAs and were able to determine a panel of nine miRNAs that were 
differentially expressed (miR-451, miR-16, miR-135b, miR-10b, miR-658, miR-205, miR-
124a, miR-372, and miR-412), allowing the identification of the body fluid origin of forensic 
biological stains using only 50 pg of total RNA [13]. Other study performed by Weber and 
co-workers examined the presence of miRNAs in 12 human body fluids of five healthy 
donors, concluding that the miRNAs tested were present in all fluids analyzed and showed 
distinct compositions in different fluid types [5]. Zubakov and colleagues screened a set of 
718 human miRNA markers in forensically relevant body fluids (saliva, venous blood, 
menstrual blood, semen and vaginal secretion), finding that two miRNA markers for blood 
(miR-144 and miR-185) and two for semen (miR-135a and miR-891a) were suggestive to 
be most useful for body fluid identification in forensic applications [72]. 
Peripheral blood fractions miRNAs profiles associated with diseases could also 
play a key role in forensic sciences, namely in the identification of victims and suspects or 
in the determination of the cause of death. For example, regarding the first case, in an 
investigation where there is an unidentified corpse, the determination of the best 
peripheral blood fraction to profile the miRNA expression, and the posterior corresponding 
analysis could indicate what type of diseases were present and lead to the victim 
identification, through the consultation of medical records. In a similar situation, in a crime 
scene, in which a possible blood stain was found, but a DNA comparison to blood 
samples from suspects can’t be performed, because that stain is not viable for DNA 
extraction and analysis, considering that miRNAs are much more stable, this same 
sample might allow a miRNA analysis, which might indicate specific pathologies of the 
sample donor, which could be crucial information to narrow down the suspects list. Or 
even, in a forensic investigation, where there isn’t permission for the collection of blood 
samples from the suspects to compare to a presumable blood stain that was found in the 
crime scene, in this situation, a miRNA profiling could also uncover eventual pathologies 
of donor of the crime scene sample. In the second case, when the cause of death is not 
apparent to the macroscopic/histological level or in sudden death cases, the presence of 
certain blood fractions miRNAs associated with diseases may indicate more clearly the 
factors that have caused the death. 
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1.6. Potential microRNA profile for peripheral blood fractions identification 
 
Some miRNAs, due to theirs expression patterns in biological samples, have a 
higher potential of being specific of different fractions of peripheral blood and, therefore, 
could be used as biomarkers for plasma, serum, and blood cells. According to Weber and 
co-workers, miR-369-3p and miR-801 are unique to the plasma when compared to other 
body fluids such as urine, saliva, and seminal fluid [5]. Similarly, in blood cells, Wang and 
colleagues reported that miR-24-1* (currently referred to as miR-24-1-5p) is present in 
blood cells (leukocytes, erythrocytes and platelets), being absent in plasma and serum 
[29]. In the case of serum, it is known that miR-16 (currently referred to as miR-16-5p) is 
abundant in this fraction [73]. Regarding the fact of the presence of this miRNA in plasma, 
in the literature there is contradictory information, since Weber and co-workers didn’t 
detected miR-16-5p in plasma and Blondal and colleagues reported that miR-16-5p is 
present in plasma [5, 74].  
Due to the information previously described, these four miRNAs (miR-369-3p, miR-
801, miR-24-1-5p and miR-16-5p) exhibit a higher potential of being exclusive of the 
fractions of peripheral blood, and therefore, were selected for this study. 
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2. OBJECTIVES 
 
 
2.1. Main objective 
 
The main objective of the present study is the identification of a miRNA profile 
used for biological identification of the different fractions of peripheral blood, namely, 
plasma, serum and white blood cells. 
 
 
2.2. Specific objectives 
 
1) Systematically revision of the literature to define the miRNA profile to be evaluated 
in biological samples (plasma, serum and white blood cells samples); 
2) Detection and determination of the expression levels of miR-801, miR-369-3p, 
miR-16-5p and miR-24-1-5p in plasma, serum and white blood cells peripheral 
blood fraction samples; 
3) Specificity and sensitivity analysis regarding the miRNA profile used in the 
identification of the peripheral blood fractions. 
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3. MATERIAL & METHODS 
 
 
3.1. Study population, sample collection and processing 
 
Peripheral venous blood samples were collected from 22 Caucasian healthy adult 
volunteers (17 females and 5 males) from the North of Portugal, with a mean age of 46.3 
± 17.8 years. The selected individuals didn’t have any pathologic conditions, in order to 
prevent eventual alterations in the miRNA profiles due to certain pathologies and to 
assure the validity of the results. All samples were collected after all individuals signed a 
written informed consent to participate in the study, according to the principles of the 
Helsinki Declaration. 
For each donor were collected two tubes, one with anticoagulant (for the collection 
of plasma and white blood cells), and another one without anticoagulant (for the collection 
of serum). The blood samples were centrifuged during 5 minutes at 2500 rpm at room 
temperature. After this initial centrifugation, serum and plasma were collected from the 
respective tubes and stored at -80ºC until molecular analysis. In order to isolate the blood 
cells, the whole blood samples were transferred to a 50 mL tube, to which was added 1x 
AKE (ammonium chloride, potassium hydrogen phosphate and EDTA). The samples were 
then frozen for 30 minutes at -20ºC and consequently centrifuged during 10 minutes at 
2500 rpm at room temperature. The supernatant was discarded and the resulting pellet 
was washed using 30 mL of 1x PBS (Phosphate buffered saline) and centrifuged during 
10 minutes at 2500 rpm at room temperature. The supernatant was again discarded and 
the pellet was diluted in 1mL of TriPure® Isolation Reagent (Roche Applied Science®). 
 
 
3.2. microRNA extraction, cDNA synthesis and relative quantification 
 
The plasma, serum and blood cell samples miRNA extraction were carried out 
from 350L of the initial sample, using the GRS microRNA Kit (Grisp®), according to the 
manufacturer's instructions, with slight modifications in the initial steps. Briefly, for the 
extraction of plasma and serum miRNAs, we used 35L of miRNA buffer and 385L of 
phenol-chloroform. In the case of the WBCs samples, the lysis buffer wasn’t used, as 
these samples were conserved in TriPure® Isolation Reagent (Roche Applied Science®), 
which had already caused the lysis of the cells, and 14L of miRNA buffer, as well as 
70L of phenol-chloroform were added to the 350L of the initial sample. 
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Subsequently, to evaluate the quantity and quality of RNA, 260/280nm and 
260/230nm ratios and RNA concentration of each sample were determined with 
NanoDrop® ND-1000. 
The cDNA synthesis (RT-PCR) was performed using the TaqMan® MicroRNA 
Reverse Transcription Kit according the manufacture instructions (Applied Biosystems®), 
wherein the extracted miRNAs were used as a template.  
 In order to quantify the miRNA expression levels, quantitative real-time PCR 
(qPCR) assays were then performed with a StepOne™ System. The reactions were 
performed using 1x TaqMan® Fast Advanced Master Mix (Applied Biosystems®), with 1x 
probes to amplify the target miRNAs (Taqman MicroRNA Assays – miR-369-3p: 000557, 
miR-801: 001994, miR-16-5p: 000391, miR-24-1-5p: 002440 and RNU-48: 001006) and 
cDNA sample. RNU-48 was used as the endogenous control. TaqMan® was selected over 
SYBR green and other dye-based technologies, since it is a fluorophore-tagged probe-
based chemistry, and it is known to have high specificity, reproducibility and sensitivity 
[75]. The PCR reactions were incubated in 48-well plate at 95ºC for 20 seconds, followed 
by 45 cycles of 95ºC for 1 second and 60ºC for 20 seconds. A negative control was 
included in all reactions and for each reaction two replicas were used. The resulting data 
was analyzed with the StepOne Software v2.2 (Applied Biosystems®). 
 
 
3.3. Statistical Analysis 
 
The statistical analysis of the data was carried out with the computer software 
IBM®SPSS®Statistics (Version 22.0).  
The 2−ΔΔCt method (Livak method) and the Student's t test were used, in order to 
assess the statistical differences in the expression levels of the normalized miRNAs. 
The real-time PCR assays originated Ct (Cycle threshold) values for each 
combination of miRNA assay-sample. These values are correspondent to the cycle 
number of the early exponential phase of the amplification reaction and, therefore, are 
inversely proportional to the relative expression levels or quantity of the miRNA in the 
sample tested. Thus, the mean of the Ct values within each sample type was determined 
and, in order to normalize the results, the difference between the mean Ct values of the 
target and the mean Ct values of the endogenous control (RNU-48) was assessed. This 
number is designated as the ΔCt (ΔCt = Cttarget – Ctendogenous control). 
The fold change values were calculated by the formula 2-ΔΔCt, following the 
equations in Figure 4. 
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Figure 4 – Equation for the determination of the  ΔΔCt̅̅ ̅̅ ̅̅  values for (a) serum vs WBCs; (b) plasma vs. WBCs 
and (c) serum vs. plasma. 
 
 
The odd ratio (OR), specificity, sensitivity, positive predictive value or precision 
(PPV), negative predictive value (NPV), accuracy (ACC) values, as well as the receiver 
operating characteristic (ROC) curves were used to evaluate the potential of miR-24-1-5p 
as a WBCs biomarker. 
 
  
(a)  ΔΔCt̅̅ ̅̅ ̅̅  = ΔCt̅̅ ̅̅̅serum - ΔCt̅̅ ̅̅̅WBCs 
 
(b) ΔΔCt̅̅ ̅̅ ̅̅  = ΔCt̅̅ ̅̅̅plasma - ΔCt̅̅ ̅̅̅WBCs 
 
(c) ΔΔCt̅̅ ̅̅ ̅̅  = ΔCt̅̅ ̅̅̅serum - ΔCt̅̅ ̅̅̅plasma 
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4. RESULTS & DISCUSSION 
 
 
4.1. microRNA detection frequencies 
 
Figure 5 displays the miRNA detection frequencies of the four studied miRNAs in 
serum, plasma and WBCs, i.e. for each peripheral blood fraction, the graphic shows the 
percentage of cases in which the miRNAs were detected.  
Through the analysis of this figure, we can conclude that miR-801 and miR-16-5p 
were both detected in the majority (95%) of the serum, plasma and WBCs samples tested. 
Moreover, these miRNAs have a more uniform distribution throughout the fractions, when 
compared to miR-369-3p and mir-24-1-5p, which were the miRNAs that exhibited more 
variations in the detection frequency in the several peripheral blood fractions. Overall, and 
based on the detection frequencies, miR-24-1-5p appears to be the miRNA with major 
differences in the fractions, as it was detected in 91% of the WBCs samples tested and 
only in 32% of the plasma samples and 5% of the serum samples tested.  
 
 
 
Figure 5 – miRNA detection frequencies in percentage (%) of miR-801, miR-369-3p, miR-16-5p and miR-24-
1-5p in serum, plasma and white blood cells. 
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4.2. microRNA relative quantification in peripheral blood fractions 
 
Figure 6 exhibits the results of the miRNA relative quantification across the four 
miRNAs tested (miR-801, miR-369-3p, miR-16-5p and miR-24-1-5p) in the peripheral 
blood fractions (serum, plasma and WBCs). The selected miRNAs show different 
expression patterns according to the peripheral blood fractions tested. MiR-801, miR-369-
3p and miR-16-5p are expressed in all of the peripheral blood fractions, leading us to 
consider that these miRNAs could be good biomarkers for whole blood identification. 
However, these miRNAs should be tested in other body fluids in order to determine theirs 
effective potential as a blood biomarker. The higher expression levels of these miRNAs 
are observed in serum, followed by plasma and, lastly, in WBCs. This is a very interesting 
result, considering that in the majority of studies, plasma is preferentially used instead of 
serum. Based on our results, serum seems to be the optimal peripheral blood fraction for 
miRNA analysis, since this fraction exhibits higher miRNA content. Furthermore, within 
these three miRNAs, miR-16-5p is the one that exhibits higher expression levels 
throughout the fractions of peripheral blood, thus it might have an important role in a 
blood-related process. In fact, according to the literature, miR-16-5p contributes to the 
regulation of mammalian hematopoiesis, through the control of the terminal stages of 
hematopoietic development [76, 77]. Moreover, a study where the variability of miRNAs in 
whole blood stored until 12 hours at room temperature was assessed concluded that miR-
16-5p was able to remain unaltered despite of the room temperature [78]. This stability of 
miR-16-5p, combined with its expression pattern in peripheral blood fractions, makes this 
miRNA an ideal biomarker for whole peripheral blood identification. 
On the other hand, miR-24-1-5p is the miRNA that reveals a more differentiated 
expression pattern in the peripheral blood fractions. The expression levels of this miRNA 
were significantly more elevated in plasma in comparison to WBCs (P=0.001) (Figure 6). 
The mean -ΔCt values of miR-24-1-5p in serum are not represented in Figure 6, as this 
miRNA was only detected in one of the 22 serum samples tested. The fact that there were 
detected higher expression levels of miR-24-1-5p in plasma rather than in WBCs might 
appear to go against what was found through the miRNA detection frequency analysis. 
However, when interpreting the relative quantification results we must consider that the 
number of samples used to determine these values was quite different: this miRNA was 
found only in 7 plasma samples and the mean of the respective quantification is being 
compared against the relative quantification of 20 WBCs samples. We can conclude that 
these results related to the expression of miR-24-1-5p can represent an addition to the 
existent data. To the best of our knowledge, the only study to date that analyzes the 
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expression of this miRNA in the several fractions of peripheral blood was performed by 
Wang and co-workers, in which the peripheral blood fractions of 10 individuals were 
tested [29]. This study detected miR-24-1-5p in blood cells (leukocytes, erythrocytes and 
platelets), and not in plasma or serum [29]. In the present work, we took a step forward 
and analyzed the miRNA content of plasma, serum and WBCs from 22 individuals.  
 
 
Figure 6 – miRNA relative quantification of miR-801, miR-369-3p, miR-16-5p and miR-24-1-5p in serum, 
plasma and white blood cells. (mean ± standard error of mean). 
 
In Table 2, the fold change in the miRNAs expression in the different peripheral 
blood fractions allow us to evaluate and compare the differences between the expression 
levels of each of the selected miRNAs in two types of peripheral blood fractions.  
 
Table 2 – Fold change values, and correspondent P values of miR-801, miR-369-3p, miR-16-5p and miR-24-
1-5p in serum, plasma and white blood cells (WBCs).  
 
Fold change (2
-ΔΔCt
) 
(P values) 
 miR-801 miR-369-3p miR-16-5p miR-24-1-5p 
Serum vs. WBCs 
28.64 
(P<0.001) 
942.27 
(P<0.001) 
461.44 
(P<0.001) 
* 
Plasma vs. WBCs 
2.45 
(P=0.097) 
129.79 
(P<0.001) 
22.63 
(P<0.001) 
70.03 
(P=0.001) 
Serum vs. Plasma 
11.71 
(P<0.001) 
7.26 
 (P=0.109) 
20.39 
(P<0.001) 
* 
*Not calculated, since this miRNA was only detected in one serum sample. 
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The analysis of the miRNA expression levels in serum comparing to WBCs levels 
reveals that miR-801, miR-369-3p and miR-16-5p are, approximately, 29, 942 and 461 
times, respectively more expressed in serum (P<0.001). The comparison of plasma vs. 
WBCs indicates statistically significant differences in miR-369-3p, miR-16-5p and miR-24-
1-5p expression. These miRNAs are approximately 130, 23 and 70 times more expressed 
in plasma in comparison to WBCs (P<0.001; P<0.001 and P=0.001, respectively). As it 
was mentioned early, we need to approach these results with caution and in the light of 
the miRNA detection frequencies. Thus, for miR-24-1-5p the interpretation may not be as 
straightforward as one might think, as the 70 fold change value might not be a good 
reflection of the results, because it is based in the relative quantification of only 7 plasma 
samples. In order to assess whether or not miR-24-1-5p can be used as a WBCs 
biomarker, further statistics need to be performed (see point 4.4.). Regarding the serum 
vs. plasma fold change expression analysis, the values obtained reveal that miR-801, 
miR-369-3p and miR-16-5p are, respectively, 12, 7 and 20 times more expressed in 
serum than in plasma (P<0.001; P=0.109 and P<0.001, respectively). 
 The fold change analysis achieved lead us to conclude that miR-16-5p could be a 
good biomarker for serum identification, as its expression values allow us to distinguish 
this blood fraction from plasma and WBCs samples. Additionally, as it was mentioned 
early, this miRNA could also be a good biomarker for whole peripheral blood identification, 
since it showed high expression levels in all the fractions. In other words, if the screening 
of miR-16-5p in an unknown fluid indicates its presence, we can propose that the fluid in 
question is blood. 
 According to our results, for the miRNAs tested we observed that WBCs was the 
fraction that exhibit lower expression levels (Figure 6, Table 2). This is an interesting 
result, especially when taking into account that miRNAs are produced in cells and, hence, 
without any additional knowledge, it would be expected to find higher expression levels in 
WBCs. This illustrates the fact that miRNAs, despite originating in cells, can and do, 
indeed, exhibit different expression patterns amongst the fluid or tissue tested, due to the 
fact that cells are able to export miRNAs into the extracellular environment [3]. In this 
particular case, we observed higher expression levels in serum, which means that, for 
these miRNAs, there is a larger quantity of miRNA molecules in serum, in comparison to 
WBCs and plasma. For miR-24-1-5p, as stated early, the interpretation of the results isn’t 
as straightforward as it is for the other miRNAs, and, with these results we cannot yet 
dismiss this miRNA as a WBCs biomarker. 
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4.3. microRNA profile according to age and gender 
 
In this section, we analyzed the relative expression of the miRNAs tested (miR-
801, miR-369-3p, miR-16-5p and miR-24-1-5p) in the peripheral blood fractions (serum, 
plasma and WBCs) according to the age and gender. 
Since our study population had a median age of 48.5, we divided the results in two 
different groups (< 48 years and ≥ 48 years). 
As shown in Figure 7, the majority of miRNAs showed no statistically significant 
differences according to the age in the three samples tested (serum, plasma and WBCs). 
The only case that exhibited significant differences was miR-369-3p in serum and plasma. 
According to the results, the expression levels of miR-369-3p were significantly higher in 
young individuals (age < 48 years) than in the older group (age ≥ 48 years) in serum 
(P=0.027) and in plasma samples (P=0.023).  
 
Figure 7 – miRNA relative quantification of miR-801, miR-369-3p, miR-16-5p and miR-24-1-5p in serum, 
plasma and white blood cells (WBCs) according to age (mean ± standard error of the mean; * P < 0.050). 
 
In the analysis according to gender, the situation is similar to what it was observed 
for age, since predominantly weren’t found any statistically significant differences 
according to this characteristic, with the exception of miR-16-5p in serum (P=0.027) and 
miR-801 in WBCs (P=0.025), which were the only cases that exhibited significant 
differences, i.e., the expression levels of miR-801 in WBCs and of miR-16-5p in serum 
were significant higher in males, than in females (Figure 8). 
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Figure 8 – miRNA relative quantification of miR-801, miR-369-3p, miR-16-5p and miR-24-1-5p in serum, 
plasma and white blood cells (WBCs) according to gender. (mean ± standard error of the mean; * P < 0.050). 
 
 
4.4. Specificity and sensitivity analysis of miR-24-1-5p as a WBCs biomarker 
 
In order to clarify and evaluate the effective potential of miR-24-1-5p as a WBCs 
biomarker, a ROC curve was constructed and odd ratio (OR), specificity (or true negative 
rate, TNR), sensitivity (or true positive rate, TPR), positive predictive value or precision 
(PPV), negative predictive value (NPV) and accuracy (ACC) values were determined 
(Table 3, Figure 9). These statistics were performed since they are able to reflect the 
ability of the correct identification of a peripheral blood fraction as WBCs or non-WBCs 
(serum and plasma) based on the detection or non-detection of this miRNA in the sample 
in question [79, 80]. 
The odd ratio (OR) represents the odds of the sample being WBCs, given that 
miR-24-1-5p is present, compared to the odds of the sample being plasma or serum in the 
presence of miR-24-1-5p [81]. The specificity reveals the proportion of the non-detection 
of miR-24-1-5p in a sample that isn’t WBCs (serum and plasma) [80]. On the other hand, 
the sensitivity reflects the proportion of the detection of miR-24-1-5p in WBCs samples 
[80]. The positive predictive value (PPV) is the proportion of WBCs samples identified in 
which miR-24-1-5p was detected, whereas the negative predictive value (NPV) indicates 
the proportion of serum and plasma in the samples in which miR-24-1-5p wasn’t detected 
[80]. Lastly, the accuracy (ACC) is the proportion of correctly identified fractions [80]. 
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According to our results, we observed that the presence of miR-24-1-5p in 
biological samples presents a likelihood of 45 times higher to be WBCs than serum or 
plasma (OR=45) (Table 3, Figure 9). Moreover, the specificity of miR-24-1-5p is 81.82%, 
and the sensitivity is 90.91%. Additionally, the PPV value is 71.43%, and the NPV value is 
94.74%. The ACC is 84.85%, in other words, with the screening of miR-24-1-5p in an 
unknown fraction, 84.85% of the samples tested are correctly identified as WBCs or non-
WBCs (serum and plasma). These results suggest that miR-24-1-5p is a potential 
biomarker for WBCs identification. 
 
Table 3 – Odd Ratio (OR), specificity, sensitivity, positive predictive value or precision (PPV), negative 
predictive value (NPV) and accuracy (ACC) values for the evaluation of miR-24-1-5p as a WBCs biomarker. 
  
OR 
 
 
Specificity 
(%) 
 
Sensitivity 
(%) 
 
PPV 
(%) 
 
NPV 
(%) 
 
 
ACC 
(%) 
 
 
All samples 
 
45 81.82 90.91 71.43 94.74 84.85 
Age 
 
< 48 years 
 
10 94.44 100.00 90.00 100.00 96.30 
≥ 48 years 
 
14 
 
73.08 
 
84.62 
 
61.11 
 
90.48 
 
76.92 
 
Gender 
 
Female 
 
92 85.29 94.12 76.19 96.97 88.00 
Male 
 
92 
 
70.00 
 
80.00 
 
57.14 
 
87.50 
 
73.33 
 
 
 
Figure 9 – ROC curve of miR-24-1-5p as a WBCs biomarker. AUC – Area under the curve. 
AUC = 0.864 
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Furthermore, we analyzed the efficiency of miR-24-1-5p in the identification of 
WBCs according to age and gender (Table 3). We observed that the reliability of this 
miRNA remained elevated across all the groups tested, exhibiting only a small reduction 
in the statistic values in the male group, comparing to the female and in the ≥ 48 years 
age range, in comparison to the < 48 years age group. Thus, this miRNA appears to be 
more effective in younger individuals and in females. A factor that might have impacted 
the lower values within the male group is the number of individuals, which were only 5, 
while the female group consisted of 17 individuals. Moreover, we observed that the miR-
24-1-5p ROC curve has an area under the curve (AUC) of 0.864 (Figure 9). The AUC 
ranges between 0 and 1, wherein higher values indicates a superior test performance [80, 
82]. Thus, in this particular situation, the AUC value of 0.864 indicates that the miR-24-1-
5p screening has a probability of 86.4% to correctly identify two samples, one of which is 
WBCs and the other is non-WBCs (serum and plasma). Based on these results, we can 
state that miR-24-1-5p can be a biomarker for WBCs identification. 
In order to better understand the significance of our results regarding the WBCs 
identification, we compared the specificity, sensitivity and AUC values of miR-24-1-5p to 
the other tested miRNAs (miR-801, miR-369-3p and miR-16-5p) (Table 4). These results 
demonstrate that miR-24-1-5p has the higher specificity and AUC values and is, in fact, 
the miRNA with the better differentiation potential between WBCs and the other examined 
fractions (serum and plasma). 
 
 
Table 4 – Comparison of the specificity, sensitivity and area under the curve (AUC) values for the 
identification of WBCs, of miR-24-1-5p with miR-369-3p, miR-801 and miR-16-5p. 
 
miRNAs 
 
Specificity (%) 
 
Sensitivity (%) AUC 
 
miR-24-1-5p 
 
81.8 90.9 0.864 
 
miR-801 
 
 
6.8 
 
95.5 0.511 
 
miR-369-3p 
 
25.6 100.0 0.628 
 
miR-16-5p 
 
4.5 95.5 0.500 
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We also performed a comparison of the specificity and sensitivity values of miR-
24-1-5p in our study with previously establish forensic and clinic biomarkers/tests that are 
currently used or that its use has been suggested (Table 5). For example, Ethyl 
Glucuronide, an ethanol metabolite used to test ethanol consumption in forensic 
scenarios, when tested in urine can discriminate between nondrinkers and individuals 
sober more than 4 days vs. individuals that drank in the recent 4 days with a sensitivity of 
83.50% and a specificity of 68.30% [83]. Other example is the initial arterial lactate level, a 
parameter that can be detected in blood, which was been identified as potential prognostic 
value of acute paraquat (herbicide widely used in agriculture) poisoning and has a 
specificity of 79.20% and a sensitivity of 84.60% [84]. We can additionally mention the 
Papanicolaou test, which is a well-known and frequently used test in clinical practice for 
cervical-cancer screening [85]. The specificity of this test for cervical intraepithelial 
neoplasia of grade 2 or 3 identification is 96.80%, whereas the sensitivity is 55.40% [85]. 
Based on our results we can verify that miR-24-1-5p, not only displays elevated 
levels of OR, specificity, sensitivity, PPV, NPV, ACC, and AUC but also, exhibits higher 
specificity and sensitivity levels than some other tests mentioned in the literature, and, 
therefore, has a potential to be a remarkable biomarker for WBCs identification. 
 
 
Table 5 – Comparison of specificity and sensitivity values of miR-24-1-5p for WBCs identification and 
currently/potential used biomarkers/tests, such as the Ethyl Glucuronide (for ethanol consumption 
identification), the initial arterial lactate level (for acute paraquat poisoning) and the Papanicolaou test (for 
cervical-cancer screening). 
 
Biomarkers 
 
 
Specificity (%) 
 
Sensitivity (%) 
 
References 
 
miR-24-1-5p 
 
 
81.82 
 
90.91 
 
Current work 
 
Ethyl Glucuronide 
 
 
68.30 
 
83.50 
 
[83] 
 
Initial arterial lactate 
level 
 
 
79.20 
 
84.60 
 
[84] 
 
Papanicolaou test 
 
 
96.80 
 
55.40 
 
[85] 
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5. CONCLUSION & FUTURE PERSPECTIVES 
 
The use of miRNAs as biomarkers for body fluid and pathologies identification as 
an auxiliary method in the forensic investigation, notwithstanding being a relatively recent 
field, it is a very promising area. Furthermore, as it was mentioned throughout this work, 
peripheral blood miRNAs are very promising biomarkers in forensic investigation, having 
several applications. In the case of body fluid identification, the detection of the blood-
specific miRNAs (whether these being whole blood, plasma, serum or blood cell specific 
miRNA) might be very useful to the identification of the donor of the sample, as it helps, 
for instance, in the identification of possible DNA collection sources. Another application, 
as stated early, is the fact that miRNAs with a differentiated expression pattern between 
heathy individuals and individuals with certain pathologies can be very useful in the 
identification of suspects and/or victims in a forensic investigation and, therefore, might 
help to reduce the list of suspects. Additionally, since miRNAs have a high stability and 
can be detected even in degraded samples, with the constant increasing knowledge in 
this area, eventually, they could allow the legal acceptance of this type of samples, and, 
consequently, could revolutionize the way evidences are processed, analyzed and used in 
court. 
However, despite all the advantages of the use of miRNAs as biomarkers, 
additional studies are necessary to overcome the information gaps existent, for example, 
in respect to the miRNA origin in the fractions of peripheral blood, as well as the 
mechanism in which these miRNAs reach the bloodstream. 
 Our results demonstrated that all of the miRNAs tested were found in, at least one 
sample of each peripheral blood fraction, however, we were able to detect different 
expression patterns. The main conclusions reached are the following: (1) the OR, 
specificity, sensitivity, PPV, NPV, ACC and AUC values of miR-24-1-5p in WBCs 
identification reveal that this miRNA can be a biomarker for WBCs identification; (2) when 
compared to the other fractions, as serum exhibited the higher miRNA expression levels 
for miR-801, miR-369-3p and miR-16-5p, this fluid represents the best option for miRNA 
analysis; (3) since miR-801, miR-369-3p and miR-16-5p were expressed throughout all 
the blood fractions tested, these miRNAs could be biomarkers for whole blood 
identification, however, in order to assess theirs effective potential as a blood biomarkers 
it would be essential to test these three miRNAs in other body fluids; (4) miR-16-5p could 
also be a biomarker for serum, however it should be tested in a larger set of samples, in 
order to allow the clarification of its potential and its use as a serum biomarker should be 
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performed with caution, as it quantification exhibited statistically significant differences 
according to gender (Table 6). 
 
 
Table 6 – Main conclusions reached concerning the biomarker potential of the analyzed miRNAs. 
 
miRNAs 
 
 
Biomarker 
 
 
 
miR-24-1-5p 
 
 
WBCs 
 
 Detected almost exclusively in WBCs 
 Sensitivity of 90.91% and specificity of 81.82% for 
WBCs identification 
 
 
miR-16-5p 
 
 
Serum  
 
 
Peripheral blood 
 
 
 Overly expressed in serum, comparing to plasma 
and WBCs (statistically significant) 
 
 Expressed in all peripheral blood fractions 
 
miR-801 and 
miR-369-3p 
 
 
Peripheral blood 
 
 Expressed in all peripheral blood fractions 
 
 
Furthermore, the fact that, overall, the miRNA expression pattern of the analyzed 
miRNAs didn’t reveal any major differences between samples from individuals of different 
gender or age, in a forensic perspective, represents a solid result, since that, in forensic 
body fluid identification what is desirable is a miRNA that could allow the correct 
identification of the fluid/fraction throughout the population, without displaying individual 
variations. 
Overall, our results demonstrated that miR-801, miR-369-3p and miR-16-5p could 
be biomarkers for whole blood identification; miR-16-5p could additionally be a biomarker 
for serum identification and miR-24-1-5p for WBCs identification.  
In the future it would be useful to work towards the standardization of the 
procedures for miRNA analysis, in order to allow a more reliable interpretation of the 
results between studies. Moreover, as future perspectives it would be also interesting to 
explore the expression patterns and levels of these and others miRNAs in peripheral 
blood fractions in a larger and diverse set of samples, to uncover other miRNAs that could 
be used as biomarkers for these fractions, as well as possible associations with pathologic 
conditions. Particularly, it would be interesting to pursue this line of investigation for miR-
24-1-5p. Since the present work uncover that this miRNA is a good biomarker for WBCs, 
the search for potential pathologic conditions that could be identified through the detection 
of alterations in its normal expression levels, could be a major tool in forensic 
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investigations, for example, in the determination of the cause of dead. Thus, the 
improvement and increase of knowledge in this area, could lead to the widespread use of 
miRNAs in forensic labs and, consequently, these molecules could one day play a key 
role in forensic investigations. 
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Abstract 
 
MicroRNAs (miRNAs) are small non-coding RNAs, with a length of 18 to 24 
nucleotides that play a regulatory role in several cellular processes. Since their discovery, 
they have been identified in cells, tissues, organs, and body fluids and their potential as 
molecular biomarkers for the diagnosis of various pathologic conditions has been 
explored. However, little is known about the origin of the extracellular miRNAs and what 
factors influence the levels of circulating miRNAs. This information could help the 
refinement of miRNAs as more effective biomarkers. Additionally, the identification of the 
origin of miRNAs may prove to be very useful in the association of particular miRNAs with 
specific pathologies. 
This review aims to gather information concerning the origin of miRNAs in plasma 
and serum, as well as to assess their potential to be use as biomarkers for these 
peripheral blood fractions. 
 
